Cargando…
Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine
In line with current microbial risk reduction efforts, pathogen inactivation (PI) technologies for blood components promise to reduce the residual risk of known and emerging infectious agents. The implementation of PI of labile blood components is slowly but steadily increasing. This review discusse...
Autor principal: | Seltsam, Axel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722787/ https://www.ncbi.nlm.nih.gov/pubmed/29255710 http://dx.doi.org/10.3389/fmed.2017.00219 |
Ejemplares similares
-
Editorial: Transfusion Medicine and Blood
por: Prudent, Michel, et al.
Publicado: (2019) -
How Can Eastern/Southern Mediterranean Countries Resolve Quality and Safety Issues in Transfusion Medicine?
por: Haddad, Antoine, et al.
Publicado: (2018) -
Toward the Relevance of Platelet Subpopulations for Transfusion Medicine
por: Handtke, Stefan, et al.
Publicado: (2018) -
Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation
por: Kleinman, Steve, et al.
Publicado: (2015) -
Emerging Pathogens in Transfusion Medicine
por: Dodd, Roger Y.
Publicado: (2010)